7 results

Design of a New Peptide Substrate Probe of the Putative Biomarker Legumain with Potential Application in Prostate Cancer Diagnosis ex vivo

Journal Article
Mathur, S., Turnbull, A., Akaev, I., Stevens, C., Agrawal, N., Chopra, M., & Mincher, D. (2020)
Design of a New Peptide Substrate Probe of the Putative Biomarker Legumain with Potential Application in Prostate Cancer Diagnosis ex vivo. International Journal of Peptide Research and Therapeutics, 26, 1965-1980. https://doi.org/10.1007/s10989-019-09994-1
The lysosomal endoprotease legumain (asparaginyl endoprotease) has been proposed as a putative biomarker in prostate tumours, in which the enzyme is markedly overexpressed. Ov...

Development of mitochondria- and protease-specific prodrugs in the potential treatment of parasitic helminth infections

Presentation / Conference
Oluwadare, E., Rehan, A., Ding, Y., Turnbull, A., Malone, E., Mincher, D., & Proudfoot, L. (2016, September)
Development of mitochondria- and protease-specific prodrugs in the potential treatment of parasitic helminth infections. Poster presented at Molecular & Cellular Biology of Helminth Parasites X, Hydra, Greece
Anthelmintic resistance and the shortage of new drugs represent an urgent need for the development of novel anti-parasite drugs with effective delivery to the target site. Red...

Design and evaluation of novel theranostic fluorogenic dual probe-prodrug in cancer

Journal Article
Mathur, S., Mincher, D., Turnbull, A., Stevens, C., & Poole, A. (2016)
Design and evaluation of novel theranostic fluorogenic dual probe-prodrug in cancer. European Journal of Cancer, 61, S142. https://doi.org/10.1016/s0959-8049%2816%2961501-0
Background: In spite of major advances in the diagnosis and treatment of cancer, there remains a paucity of biomarkers for early detection. Legumain is a potential cancer biom...

Oxoazabenzo[de]anthracenes conjugated to Amino Acids: Synthesis and evaluation as DNA-binding antitumor agents.

Journal Article
Dias, N., Goossens, J., Baldeyrou, B., Lansiaux, A., Colson, P., Di Salvo, A., …Bailly, C. (2005)
Oxoazabenzo[de]anthracenes conjugated to Amino Acids: Synthesis and evaluation as DNA-binding antitumor agents. Bioconjugate Chemistry, 16(4), 949-958. https://doi.org/10.1021/bc050065x
We report the synthesis of an original series of oxoazabenzo[de]anthracenes conjugated to an amino acid: Ala, Phe, Pro, Lys, or Gly (4a-e, respectively). The compounds, derive...

Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model

Journal Article
Van Valckenborgh, E., Mincher, D., Di Salvo, A., Van Riet, I., Young, L., Van Camp, B., & Vanderkerken, K. (2005)
Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model. Leukemia, 19(9), 1628-1633. https://doi.org/10.1038/sj.leu.2403866
Multiple myeloma (MM) is an incurable B-cell cancer characterised by the monoclonal proliferation of tumour cells in the bone marrow (BM). It has been described that matrix me...

Anthracene derivatives as anti-cancer agents.

Patent
Mincher, D. & Turnbull, A. (2004)
Anthracene derivatives as anti-cancer agents.
The present invention relates to compounds which are based on an anthraquinone nucleus for use in medicine, particularly as anti-cancer agents which exert their effects throug...

Stereospecific synthesis of chiral caprolactone monomers from D-glucose.

Journal Article
Defossemont, G. & Mincher, D. (2003)
Stereospecific synthesis of chiral caprolactone monomers from D-glucose. Carbohydrate Research. 338, 563-565. doi:10.1016/S0008-6215(02)00490-1. ISSN 0008-6215
The synthesis and characterisation of a novel chiral bicyclic oxacaprolactone is reported. The choice of diisopropylidene- -glucose as a starting material allowed selective in...
10 results

Design, synthesis and cytotoxicity of bifunctional anticancer agents targeted to mitochondria.

2018 - date
Mohamad Kamel | Director of Studies: Dr David Mincher | Second Supervisor: Agnes Turnbull

Design and development of novel targeted anticancer drugs

2018 - date
Ewoma Akpughe | Director of Studies: Dr David Mincher | Second Supervisor: Agnes Turnbull

A global exploration of programme theory within surf therapy

2018 - 2022
Dr James Marshall | Director of Studies: Dr Brendon Ferrier | Second Supervisor: Prof Russell Martindale

Communities of constraint: An ethnographic study of Tibetan refugees navigating protracted displacement and everyday vulnerability in Nepal

2018 - date
Kyle Schwartz | Director of Studies: Dr Kiril Sharapov | Second Supervisor: Prof Richard Whitecross

Synthesis and flourescence properties of a novel legumain substrate probe

2018 - 2022
Deepthi Ravula | Director of Studies: Dr David Mincher | Second Supervisor: Agnes Turnbull

Design, synthesis and evaluation of novel and clinically used anti-cancer agents targeted intracellularly

2014 - 2021
The majority of clinically used anticancer drugs suffer from poor selectivity for tumour cells ...
Omar Mohammed | Director of Studies: Dr David Mincher | Second Supervisor: Agnes Turnbull

The development of a caenorhabtitis elegans model for the assessment of toxicity: application in the treatment of parasitic worm infections

2013 - 2017
Eyitayo Oluwadare | Director of Studies: Dr Lorna Proudfoot | Second Supervisor: Dr Eva Malone

Design and synthesis of novel prodrugs to modulate GABA receptors in cancer

2011 - 2017
Hui Zhang | Director of Studies: Dr David Mincher

Novel Anticancer Agents and Oligopeptide drug conjugates: Biochemistry of Topoisomerase Inhibition and MMP-Activation.

2001 - 2006
Dr Lesley Young | Director of Studies: Dr David Mincher | Second Supervisor: Dr Janis MacCallum

Design and Development of Novel DNA Topoisomerase Inhibitors

1994 - 2004
Agnes Turnbull | Director of Studies: Dr David Mincher